Immunogenic cell death (ICD) is a novel anti-tumour strategy. The tumour microenvironment (TME), including endothelial cells (ECs), can influence the therapeutic efficacy of ICD. My project will gain insight into the immunological role of ECs in the TME exposed to ICD-induced cancer cells, and unravel the molecular mechanisms and key elements responsible for the efficacy of ICD-induced therapy.